Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.37 |
| ▸ | FEN1 | P39748 | 4/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324403 | 0.90 | USP30 (0.44) | HPGDSGPR119USP30TP53 | |
| SCHEMBL6329178 | 0.88 | GPR119 (0.40) | HPGDSGPR119 | |
| SCHEMBL6330093 | 0.82 | GPR119 (0.43) | HPGDSGPR119TP53 | |
| SCHEMBL6323845 | 0.80 | CHRNB2 (0.47) | GPR119USP30ADORA2A | |
| SCHEMBL28642090 | 0.80 | NR1H2 (0.44) | GPR119NR1H2MEN1KMT2ATP53 | |
| SCHEMBL6324664 | 0.80 | HPGDS (0.53) | HPGDSGPR119USP30TP53 | |
| SCHEMBL928188 | 0.79 | MEN1 (0.41) | GPR119MEN1KMT2ATP53 | |
| SCHEMBL6321817 | 0.79 | GPR119 (0.38) | HPGDSGPR119USP30MEN1KMT2A | |
| SCHEMBL6329284 | 0.79 | KDM1A (0.38) | HPGDSGPR119USP30MEN1KMT2A | |
| SCHEMBL6331666 | 0.76 | GPR119 (0.54) | GPR119MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | ABBOTT LABORATORIES | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | CHRNA7, CHRNA1, CHRNA5 | HPGDS 3755/4885GPR119 69/4885ALOX5AP 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.